Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: INCY stock price vs CL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CL's multiple
Needs CL P/E.
Implied fair value · at INCY's multiple
Needs INCY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INCY FY 2025 (ended Dec 31, 2025) · CL FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
INCYTE CORPORATION · implied price per share
Bear
-$7.58
Base
-$8.91
Bull
-$10.25
COLGATE-PALMOLIVE COMPANY · implied price per share
Bear
$15.35
Base
$18.06
Bull
$20.77
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
3.83x
165.81x
Net debt / EBITDA
Leverage against operating earnings
9.31x
2.31x
Cash and equivalents
Liquid reserves on the balance sheet
$3.38B
$1.40B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
INCY vs AMGN
GILEAD SCIENCES, INC.
INCY vs GILD
VERTEX PHARMACEUTICALS INC / MA
INCY vs VRTX
REGENERON PHARMACEUTICALS, INC.
INCY vs REGN
BIOGEN INC.
INCY vs BIIB
PROCTER & GAMBLE Co
INCY vs PG
JOHNSON & JOHNSON
INCY vs JNJ
CHURCH & DWIGHT CO INC /DE/
INCY vs CHD
KIMBERLY CLARK CORP
INCY vs KMB
EDGEWELL PERSONAL CARE Co
INCY vs EPC
UNILEVER PLC
INCY vs UL
$19.78B
$8.95B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe INCY can sustain its 21.2% revenue growth and 29.5% operating margin without balance sheet deterioration, then the stock can justify a higher relative multiple; otherwise, prefer a more cautious stance because the DCF range and leverage metrics do not fully support the headline 88.3% upside.
On the stated P/E basis, INCY looks much cheaper than the implied CL-based price suggests, with current price at $120.33 versus an implied $226.64, or 88.3% upside. However, the broader valuation picture is mixed because INCY also trades above CL on P/S and below CL on P/E, while DCF and historical bands point to a materially lower fair-value range.
Supporting Metrics
